Skip to content
OpenCapital
Get started

Rhythm Pharmaceuticals, Inc. RYTM Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$51.3MMiss by $4.7M
EPS-$0.82Miss by $0.10
Revenue estimate$56.0M
EPS estimate-$0.72

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$67.7M
EPS estimate-$0.82

Financials

Q3 2025

Income statement

See full
Revenue$51.3M+54.3%
Gross profit$45.8M+55.7%
Operating income-$52.7M-20.0%
Net income-$52.9M-21.2%
EPS (diluted)-$0.82-12.3%

Balance sheet

See full
Cash & equivalents$52.1M+9.6%
Total debt$113.1M+2,707%
Total equity$148.8M+1,227%
Total assets$506.9M+39.4%

Cash flow

See full
Operating cash flow-$26.6M-5.6%
CapEx$238.3K—
Free cash flow-$29.2M-2.4%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$6.71B+110%
Enterprise value$6.77B+115%
P/S38.5×+10.1×

Profitability

See full
Gross margin89.4%+0.8pp
Operating margin-106.8%-37.8pp
Net margin-110.3%-37.8pp
FCF margin-66.5%-17.2pp

Returns & leverage

See full
Return on equity-240.4%-7.3pp
Debt / equity0.8×+0.4×
Current ratio4.7×+1.3×

Segments

By segment

See full
Single reportable segment$51.3M+54.3%

Versus estimates

Revenue

Q1 2026$60.1MBeat by $4.3MQ4 2025$57.3MBeat by $1.0M
Q3 2025$51.3MMiss by $4.7M
Q2 2025$48.5MMiss by $2.8MQ1 2025$32.7MMiss by $10.6MQ4 2024$41.8MBeat by $3.3M

Diluted EPS

Q1 2026-$0.83Beat by $0.03Q4 2025-$0.73Beat by $0.06
Q3 2025-$0.82Miss by $0.10
Q2 2025-$0.75Miss by $0.09Q1 2025-$0.81Miss by $0.12Q4 2024-$0.72Miss by $0.03

Ask the moment Rhythm Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Rhythm Pharmaceuticals, Inc. report Q3 2025 earnings?
Rhythm Pharmaceuticals, Inc. (RYTM) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Rhythm Pharmaceuticals, Inc.'s Q3 2025 revenue and EPS?
Rhythm Pharmaceuticals, Inc. reported revenue of $51.3M and eps of $-0.82 for Q3 2025.
Did Rhythm Pharmaceuticals, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $56.0M by $4.7M. EPS missed the consensus estimate of $-0.72 by $0.10.
How did Rhythm Pharmaceuticals, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 54.3% from $33.3M a year earlier and eps declined 12.3% from $-0.73.
Where can I find Rhythm Pharmaceuticals, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-105904) and the 10-Q periodic report (0001104659-25-106264) directly on SEC EDGAR. The filing index links above go to sec.gov.